Trials / Completed
CompletedNCT03580564
An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 109 (actual)
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is to evaluate the efficacy of KL-A167 a in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KL-A167 | KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W) |
Timeline
- Start date
- 2018-08-01
- Primary completion
- 2020-08-22
- Completion
- 2022-01-13
- First posted
- 2018-07-09
- Last updated
- 2023-10-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03580564. Inclusion in this directory is not an endorsement.